Physician profile
Jonathan Daniel Barnes
NPI 1376915678
$10,300.39
in general payments reported to CMS, 2019-2025
43 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,213 · 2022: $1,645 · 2023: $2,363 · 2024: $2,346 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,382 · Education: $59.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,382.16 |
| Education | $59.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,484.45 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,010.28 | 2021-2025 | Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $881.31 | 2021-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $828.10 | 2021-2025 | Dupixent |
| Genzyme Corporation | $750.08 | 2021-2025 | |
| Genentech USA, INC. | $631.07 | 2021-2025 | Xolair |
| Grifols USA, LLC | $459.67 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Mylan Specialty L.P. | $297.76 | 2021-2024 | Yupelri |
| Electromed, INC. | $273.28 | 2021-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $251.62 | 2022-2025 | Xywav |
| United Therapeutics Corporation | $248.47 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $202.13 | 2021-2024 | Glassia |
| Mallinckrodt Hospital Products INC. | $177.48 | 2022-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $165.04 | 2021-2025 | |
| Amgen INC. | $157.60 | 2021-2025 | Tezspire |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $154.58 | 2021-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $142.28 | 2021-2024 | |
| Philips North America LLC | $123.25 | 2021-2024 | (8874) Incourage |
| Resmed Corp | $115.70 | 2021-2025 | |
| Inspire Medical Systems, INC. | $114.67 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $102.63 | 2021-2024 | Capvaxive, Zerbaxa, Zinplava |
| Abbvie INC. | $91.99 | 2021 | |
| Baxter Healthcare | $65.66 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $60.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Pulmonx Corporation | $50.22 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pfizer INC. | $49.25 | 2023-2024 | |
| Ambu INC. | $44.71 | 2023 | |
| Paratek Pharmaceuticals, INC. | $32.39 | 2023 | Nuzyra |
| Vanda Pharmaceuticals INC. | $30.65 | 2021 | |
| Intuitive Surgical, INC. | $29.86 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $28.95 | 2023 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $18.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.80 | 2022 | |
| Tactile Systems Technology INC | $18.72 | 2025 | Flexitouch Plus, Nimbl |
| Axsome Therapeutics, INC. | $18.54 | 2023 | Sunosi |
| Hill-Rom Company, INC | $18.42 | 2021 | |
| Advanced Respiratory, INC | $17.90 | 2021 | |
| La Jolla Pharmaceutical Company | $16.65 | 2021 | |
| Verona Pharma, INC. | $16.59 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $14.61 | 2025 | Yupelri |
| Phadia US INC. | $13.75 | 2025 | Immunocap |
| Breas Medical, INC. | $12.07 | 2025 | Vivo 1/2, Vivo 45 Ls |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.